Clinical Commander

Back to dossier
cardio.hypertensive-emergency.encephalopathy.v1PRODUCTION
cardio.hypertensive-emergency.encephalopathy.v1

Hypertensive encephalopathy (HTN crisis with cerebral edema / AMS / papilledema)

cardiologyacuteadult
Hard-required inputs
0 / 8
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Hypertensive encephalopathy = severe HTN + cerebral edema features (AMS, papilledema, severe HA, vision change) WITHOUT focal deficit; cerebral autoregulation curve is right-shifted in chronic HTN — precipitous drop risks ischemia. Distinguish from ICH (focal deficit) and ischemic stroke (focal deficit). Route to parent engine for shared HTN-emergency arc; this dossier owns the autoregulation-aware drug + monitoring profile.

Inputs
3
Actions
0
Advance rule
Set
Advance when

encephalopathy phenotype confirmed + ICH/stroke ruled out on CT

Patient inputs (9)

Older patients have rightward-shifted cerebral autoregulation curve — precipitous BP drop risks ischemia (ACC/AHA 2025; Vaughan Lancet 2000)

Papilledema / KWB grade III-IV supports diagnosis + tracks treatment response

Rule out ICH (mandatory before BP titration) + parieto-occipital edema pattern of PRES

AKI co-presence drives nicardipine-over-nitroprusside selection (cyanide risk eGFR <30)

GCS trend during titration — rapid decline with BP drop signals overshoot through autoregulation floor

Defines crisis threshold (≥180) + drives autoregulation-aware titration (MAP ↓ ≤25% in 1 h; SBP <140-160 within 6 h)

Component of MAP calculation; DBP >120 supports emergency criterion

Focal deficit excludes hypertensive encephalopathy → routes to ICH or ischemic stroke pathway instead

Posterior reversible encephalopathy syndrome pattern confirms diagnosis when CT non-diagnostic (Vaughan Lancet 2000 PMID 10972386)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningprecipitous_bp_drop_with_neuro_decline
    GCS decline OR new focal deficit during titration — indicates BP drop has overshot through right-shifted cerebral autoregulation floor → ischemic conversion risk
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningencephalopathy_progression_to_coma
    Hypertensive encephalopathy progressing to coma / GCS <8 / posturing despite BP titration
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningnew_focal_deficit_during_treatment
    New focal neuro deficit on serial exam during treatment — reclassifies syndrome from encephalopathy to ICH or ischemic stroke
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningstatus_epilepticus_breakthrough
    Recurrent or prolonged seizures during encephalopathy — status epilepticus + ongoing PRES
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresevere_papilledema_with_vision_loss
    KWB grade IV papilledema with progressive vision loss — risk of permanent visual deficit if BP not lowered
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENTrequiredDrives monitoring threshold
Loading…

Recommended regimen

Hypertensive encephalopathy — autoregulation-aware IV titration; MAP ↓ ≤25% in 1 h; SBP <140-160 within 6 h
axis: htn_encephalopathy_autoregulation_aware
Selected axis "Hypertensive encephalopathy — autoregulation-aware IV titration; MAP ↓ ≤25% in 1 h; SBP <140-160 within 6 h" by default fallback (first axis)
  • nicardipine
    first line
    DHP_CCB
    5 mg/h IV, titrate by 2.5 mg/h q5-15 min, max 15 mg/h • IV • continuous
    triggers: hypertensive_encephalopathy, cerebral_edema_or_pres
    ACC/AHA 2025 first-line — predictable cerebral autoregulation effect; titratable; no CSF/ICP issues; preferred over labetalol given selective vasodilation
    rxcui 7396
  • clevidipine
    first line
    DHP_CCB_short_acting
    1-2 mg/h IV, titrate q90 sec • IV • continuous
    triggers: encephalopathy_with_volume_overload_concern, tight_control_required
    Ultra-short half-life allows tight control + minute-to-minute titration; lipid emulsion (avoid egg/soy allergy)
    rxcui 233603
  • labetalol
    second line
    mixed_alpha_beta_blocker
    20 mg IV q10 min (max 300 mg cumulative) OR 0.5-2 mg/min infusion • IV • bolus or infusion
    triggers: encephalopathy_with_tachycardia, nicardipine_intolerant
    Mixed α/β useful when sympathetic drive is high; no reflex tachycardia (ACC/AHA 2025)
    rxcui 6185
  • AVOID nitroprusside
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: encephalopathy_diagnosis
    Cyanide toxicity (especially eGFR <30 + duration >24 h); thiocyanate accumulation → may worsen ICP via venodilation; ACC/AHA 2025 AVOID in encephalopathy
  • AVOID hydralazine
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: encephalopathy_diagnosis
    Unpredictable BP drop magnitude + delayed onset → risk of overshoot through autoregulation floor; reserve for pregnancy phenotype
  • AVOID nimodipine
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: encephalopathy_without_sah
    Nimodipine is SAH-only indication (vasospasm prophylaxis per AHA SAH guidelines); not for general HTN encephalopathy

outpatient playbook — drug actions (1)

  1. 1. continue 4-tier oral regimen
    rxcui 17767
    Amlodipine 5-10 + lisinopril 10-40 + chlorthalidone 12.5-25 • PO • daily
    trigger: Stable maintenance
    ACC/AHA 2025

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: SBP >180 + AMS / severe headache / papilledema / vision change WITHOUT focal deficit (ACC/AHA 2025 HTN; Vaughan Lancet 2000 PMID 10972386); Funduscopy showing papilledema / hemorrhages / exudates (Keith-Wagner-Barker grade III/IV); MRI showing posterior reversible encephalopathy syndrome (PRES) / parieto-occipital edema pattern (Vaughan Lancet 2000 PMID 10972386).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Hypertensive encephalopathy (HTN crisis with cerebral edema / AMS / papilledema)** (cardio.hypertensive-emergency.encephalopathy.v1).
Scope: Hypertensive encephalopathy = severe HTN + cerebral edema features (AMS, papilledema, severe HA, vision change) WITHOUT focal deficit; cerebral autoregulation curve is right-shifted in chronic HTN — precipitous drop risks ischemia. Distinguish from ICH (focal deficit) and ischemic stroke (focal deficit). Route to parent engine for shared HTN-emergency arc; this dossier owns the autoregulation-aware drug + monitoring profile.

No severity triggers fired against current inputs.

Plan

Regimen axis: **Hypertensive encephalopathy — autoregulation-aware IV titration; MAP ↓ ≤25% in 1 h; SBP <140-160 within 6 h**.
1. nicardipine 5 mg/h IV, titrate by 2.5 mg/h q5-15 min, max 15 mg/h IV continuous (DHP_CCB, first line) — ACC/AHA 2025 first-line — predictable cerebral autoregulation effect; titratable; no CSF/ICP issues; preferred over labetalol given selective vasodilation
2. clevidipine 1-2 mg/h IV, titrate q90 sec IV continuous (DHP_CCB_short_acting, first line) — Ultra-short half-life allows tight control + minute-to-minute titration; lipid emulsion (avoid egg/soy allergy)
3. labetalol 20 mg IV q10 min (max 300 mg cumulative) OR 0.5-2 mg/min infusion IV bolus or infusion (mixed_alpha_beta_blocker, second line) — Mixed α/β useful when sympathetic drive is high; no reflex tachycardia (ACC/AHA 2025)
4. AVOID nitroprusside AVOID N/A N/A (do_not_use, contraindication substitute) — Cyanide toxicity (especially eGFR <30 + duration >24 h); thiocyanate accumulation → may worsen ICP via venodilation; ACC/AHA 2025 AVOID in encephalopathy
5. AVOID hydralazine AVOID N/A N/A (do_not_use, contraindication substitute) — Unpredictable BP drop magnitude + delayed onset → risk of overshoot through autoregulation floor; reserve for pregnancy phenotype
6. AVOID nimodipine AVOID N/A N/A (do_not_use, contraindication substitute) — Nimodipine is SAH-only indication (vasospasm prophylaxis per AHA SAH guidelines); not for general HTN encephalopathy

Setting playbook (outpatient) — Long-term cardiology + neurology + ophthalmology surveillance — secondary prevention bundle maintenance, MRI confirmation of PRES resolution, BP <130/80 maintained, secondary cause completion
7. continue 4-tier oral regimen Amlodipine 5-10 + lisinopril 10-40 + chlorthalidone 12.5-25 PO daily — Stable maintenance (ACC/AHA 2025)

Non-pharmacologic actions:
- DASH + lifestyle maintenance
- Cardiac rehab if MI overlay
- Annual ophthalmology + neurology follow-up

AVOID / contraindication checks:
- Nitroprusside_avoid_in_encephalopathy_cyanide_and_icp (ACC/AHA 2025; Vaughan Lancet 2000)
- Hydralazine_unpredictable_avoid_for_encephalopathy (ACC/AHA 2025)
- Nimodipine_sah_only_not_for_encephalopathy (AHA SAH 2023)
- Autoregulation_aware_do_not_drop_MAP_more_than_25_pct_first_hour (ACC/AHA 2025; Vaughan Lancet 2000 PMID 10972386)

Monitoring

Regimen monitoring:
- arterial line q5-15min BP (ACC/AHA 2025)
- q15-30min neuro exam first 6h (Vaughan Lancet 2000)
- GCS trend during titration (Vaughan Lancet 2000)
- fundus exam initial then 24h then daily (ESC/ESH 2024)
- serial creatinine q4-6h (ACC/AHA 2025)
- MRI at 4-6 weeks to confirm pres resolution (Vaughan Lancet 2000)

Setting (outpatient) monitoring:
- Quarterly BP
- Annual MRI if PRES history
- Annual lipid + A1c

Follow-up plan: Transition to oral 4-tier ladder once stable × 6-12 h; 1-week neuro + cardiology + ophthalmology follow-up; MRI at 4-6 wk to confirm PRES resolution; secondary cause workup
- Close-out criterion: oral regimen stable + outpatient follow-up booked

Monitoring phase: Arterial line + q5-15 min BP; q15-30 min neuro exam during first 6 h; daily fundus exam; daily BMP for AKI; serial troponin if elevated; MRI follow-up to confirm PRES resolution

Disposition

Current setting: outpatient — Long-term cardiology + neurology + ophthalmology surveillance — secondary prevention bundle maintenance, MRI confirmation of PRES resolution, BP <130/80 maintained, secondary cause completion

Disposition criteria:
- Long-term continuation; cross-link to cardio.htn.core.v1 for chronic management

Escalation triggers (move to higher acuity):
- BP rebound → return to ED
- New neuro symptom → urgent re-eval

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] GCS decline OR new focal deficit during titration — indicates BP drop has overshot through right-shifted cerebral autoregulation floor → ischemic conversion risk
- [LIFE_THREATENING] Hypertensive encephalopathy progressing to coma / GCS <8 / posturing despite BP titration
- [LIFE_THREATENING] New focal neuro deficit on serial exam during treatment — reclassifies syndrome from encephalopathy to ICH or ischemic stroke

Citations

- 2025 ACC/AHA HTN Guideline (Whelton) + ESC/ESH 2024 HTN (Mancia, PMID 38613493) + AHA/ASA 2022 ICH (PMID 35138133) — disambiguation neighbor [PMID:38316810](https://pubmed.ncbi.nlm.nih.gov/38316810/)
- Cited evidence (PMID 38613493) [PMID:38613493](https://pubmed.ncbi.nlm.nih.gov/38613493/)
- Cited evidence (PMID 10972386) [PMID:10972386](https://pubmed.ncbi.nlm.nih.gov/10972386/)
- Cited evidence (PMID 12911804) [PMID:12911804](https://pubmed.ncbi.nlm.nih.gov/12911804/)
- Cited evidence (PMID 35138133) [PMID:35138133](https://pubmed.ncbi.nlm.nih.gov/35138133/)

Last reconciled with current guidelines: 2026-05-14.
References
  • 2025 ACC/AHA HTN Guideline (Whelton) + ESC/ESH 2024 HTN (Mancia, PMID 38613493) + AHA/ASA 2022 ICH (PMID 35138133) — disambiguation neighbor — PMID:38316810
  • Cited evidence (PMID 38613493) — PMID:38613493
  • Cited evidence (PMID 10972386) — PMID:10972386
  • Cited evidence (PMID 12911804) — PMID:12911804
  • Cited evidence (PMID 35138133) — PMID:35138133